Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Capital Expenditures (2016 - 2025)

Regenxbio (RGNX) has 11 years of Capital Expenditures data on record, last reported at -$1.0 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 194.25% year-over-year to -$1.0 million; the TTM value through Dec 2025 reached $889000.0, down 63.51%, while the annual FY2025 figure was $889000.0, 63.51% down from the prior year.
  • Capital Expenditures reached -$1.0 million in Q4 2025 per RGNX's latest filing, down from $491000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $31.0 million in Q1 2021 and bottomed at -$1.0 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $6.4 million, with a median of $2.0 million recorded in 2023.
  • Peak YoY movement for Capital Expenditures: soared 570.0% in 2021, then plummeted 194.25% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $14.6 million in 2021, then plummeted by 62.57% to $5.5 million in 2022, then tumbled by 79.41% to $1.1 million in 2023, then dropped by 4.17% to $1.1 million in 2024, then tumbled by 194.25% to -$1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$1.0 million in Q4 2025, $491000.0 in Q3 2025, and $391000.0 in Q2 2025.